Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Merck Sharp + Dohme Corp.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Msd Italia S.r.l.

Barbara Attenni

Michael Rowley

Frank Narjes

Philip Jones

Philippe L Durette

Rita Scarpelli

Raffaele Ingenito

Jesus Maria Ontoria Ontoria

Cristina Gardelli

Giovanna Pescatore

Olaf Kinzel

Federica Ferrigno

Savina Malancona

Laura Llauger Bufi

Monica Donghi

Jose Ignacio Martin Hernando

Jesus Maria Ontoria

Carsten Schultz

The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. (I) 

Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection

The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

Heterocycle derivatives as histone deacetylase (HDAC) inhibitors

The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and Xare as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Thienopyrroles as antiviral agents

Growing community of inventors

Rome, Italy

Barbara Attenni